High cardiovascular drug costs may limit access to patients

An FDA advisory panel recommended the approval of alirocumab and evolocumab last week, and the cardiovascular medications are expected to be approved this summer. However, the drugs may cost up to $10,000 per year and may be too expensive for some patients, USA Today reports.